nirmatrelvir / ritonavir (Paxlovid) (n=1120) vs. placebo (n=1126)
randomized controlled trial
low risk of bias
Nirmatrelvir/ritonavir (Paxlovid)
300 mg of nirmatrelvir plus 100 mg of ritonavir every 12 hours for 5 days
Placebo
Patients were treated within five days of symptom onset.
COVID 19 outpatients
Patients with confirmed SARS-CoV-2 infection within 5 days prior to randomization, with at least 1 characteristic or underlying medical condition associated with an increased risk of developing illness from COVID-19.
Double-blind.
North and South America, Europe, Africa, and Asia.